ArticleDiseases (Basel, Switzerland)2024
The Simultaneous Use of Bladder Epicheck
Article in Diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Review
- Circulating Tumor Function: A Systems Biology Framework for Liquid Biopsy in Genitourinary Cancers.Genes · 2026Review
- Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.Journal of clinical medicine · 2026Review
- Retrospective single-center cytohistologic correlation study of fine-needle aspiration cytology for excised superficial enlarged lymph node lesions in different disease entities.Discover oncology · 2026Article
- Liquid Biopsy Biomarkers in Endometrial Cancer: Current Landscape and Future Perspectives.Biomolecules · 2026Review
- The Insulin-Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles.International journal of molecular sciences · 2026Review
- Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring.Cancers · 2026Review
- Cost-effectiveness analysis of Enfortumab vedotin and pembrolizumab for advanced urothelial carcinoma.Medicine · 2026Article
- Urinary DNA methylation biomarkers for bladder cancer diagnosis: a single center case-control study.Frontiers in oncology · 2026Article
- Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.Frontiers in oncology · 2026Article
- Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance.Frontiers in oncology · 2026Review
- Integrating transcriptomics, single-cell omics, and deep learning-based histopathological features to identifyTranslational andrology and urology · 2025Article
- Transcriptomic Profiles for Elucidating Response of Bladder Intracavitary Hyperthermic Perfusion Chemotherapy in High-Risk Nonmuscular Invasive Bladder Cancer.Cancer medicine · 2025Article
- Advancements in genetic circuits as part of intelligent biotherapy for the treatment of bladder cancer: A review.Bladder (San Francisco, Calif.) · 2025Review
- Multi-omics dissection of fatty acid metabolism heterogeneity identifies PRDX1 as a prognostic marker in bladder cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.